Literature DB >> 9502487

Persistence of Pneumocystis carinii after effective treatment of P. carinii pneumonia is not related to relapse or survival among patients infected with human immunodeficiency virus.

P M Roger1, F Vandenbos, P Pugliese, F De Salvador, J Durant, Y Le Fichoux, P Dellamonica.   

Abstract

Entities:  

Mesh:

Year:  1998        PMID: 9502487     DOI: 10.1086/517099

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

1.  Outcomes and duration of Pneumocystis jiroveci pneumonia therapy in infants with severe combined immunodeficiency.

Authors:  Ingrid S Lundgren; Janet A Englund; Lauri M Burroughs; Troy R Torgerson; Suzanne Skoda-Smith
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

Review 2.  How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation.

Authors:  Georg Maschmeyer; J Peter Donnelly
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

3.  A double whammy in an immunocompromised patient.

Authors:  Archana Baburao; Amandeep Singh; Huliraj Narayanswamy; Bhavya Shivalingaiah
Journal:  Indian J Sex Transm Dis AIDS       Date:  2020-11-11

Review 4.  Narrative review of the relationship between COVID-19 and PJP: does it represent coinfection or colonization?

Authors:  Woon H Chong; Biplab K Saha; Amit Chopra
Journal:  Infection       Date:  2021-05-31       Impact factor: 3.553

5.  Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  G Maschmeyer; J Carratalà; D Buchheidt; A Hamprecht; C P Heussel; C Kahl; J Lorenz; S Neumann; C Rieger; M Ruhnke; H Salwender; M Schmidt-Hieber; E Azoulay
Journal:  Ann Oncol       Date:  2014-05-15       Impact factor: 32.976

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.